Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
University of Wisconsin, Madison
Study ID
NCT00582166
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ibritumomab Tiuxetan (Zevalin) + Rituximab — DRUG
    Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression

Study Details

Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression

Key Dates

Start date
Jan 25, 2005
Status verified
Jul 2018
Primary completion
Mar 31, 2013
Completion
Mar 31, 2013

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ibritumomab Tiuxetan (Zevalin) with Rituximab maintenance

Primary Outcome Measure

Median Progression Free Survival (PFS) [ Time Frame: up to 5 years, 9.5 months, from first day on treatment to last follow up ]

Locations (1)

FacilityCityStateZIPSite coordinators
University Of WisconsinMadisonWisconsin53792-

Find similar trials in Madison, WI

By research site
University Of Wisconsin· Madison, WI

Related Studies